Graziano SL: Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer 17(Suppl 1): S37-S58, 1997.
Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111: 1710-1717, 1997.
Andre F, Grunenwald D, Pignon JP, Dujon A, Pujol JL, Brichon PY, Brouchet L, Quoix E, Westeel V and Le Chevalier T: Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 18: 2981-2989, 2000.
Berghmans T, Lafitte JJ, Thiriaux J, VanHoutte P, Lecomte J, Efremidis A, Koumakis G, Giner V, Ridiez M, Corhay JL, Wackenier P, Lothaire P, Mommen P, Ninane V, Sculier JP, and for the European Lung Cancer Working Party: Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy. Lung Cancer 45: 339-348, 2004.
Bollen EC, Theunissen PH, van Duin CJ, Drenth BM, van Noord JA and Blijham GH: Clinical significance of intranodal and extranodal growth in lymph node metastases of non-small cell lung cancer. Scand J Thorac Cardiovasc Surg 28: 97-102, 1994.
Inoue K, Sato M, Fujimura S, Sakurada A, Takahashi S, Usuda K, Kondo T, Tanita T, Handa M, Saito Y and Sagawa M: Prognostic assessment of 1310 patients with non-small-cell lung cancer who underwent complete resection from 1980 to 1993. J Thorac Cardiovasc Surg 116: 407-411, 1998.
Jassem J, Skokowski J, Dziadziuszko R, Jassem E, Szymanowska A, Rzyman W and Roszkiewicz A: Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification. J Thorac Cardiovasc Surg 119: 1141-1146, 2000.
Leong SS, Rocha Lima CM, Sherman CA and Green MR: The 1997 International Staging System for non-small cell lung cancer: have all the issues been addressed? Chest 115: 242-248, 1999.
Sculier JP, Paesmans M, Ninane V, Giner V, Bureau G, Lafitte JJ, Baumohl J, Thiriaux J, van Cutsem O, Recloux P, Berchier MC, Zacharias C, Mommen P, van Houtte P and Klastersky J: Evaluation of the TN sub-staging in patients with initially unresectable stage III non-small cell lung cancer treated by induction chemotherapy. The European Lung Cancer Working Party. Lung Cancer 22: 201-213, 1998.
Vansteenkiste JF, De Leyn PR, Deneffe GJ, Stalpaert G, Nackaerts KL, Lerut TE and Demedts MG: Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group. Ann Thorac Surg 63: 1441-1450, 1997.
Kanters SD, Lammers JW and Voest EE: Molecular and biological factors in the prognosis of non-small cell lung cancer. Eur Respir J 8: 1389-1397, 1995.
Sculier JP, Paesmans M, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, van Cutsem O, Schmerber J, Giner V, Berchier MC, Mommen P, Sergysels R and Klastersky J: Facteurs pronostiques des cancers bronchiques non à petites cellules au stade avancé: expérience de l'European Lung Cancer Working Party. Rev Mal Respir 14: 445-449, 1997.
D'Arnico TA, Massey M, Herndon JE, Moore MB and Harpole DH Jr: A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 117: 736-743, 1999.
Pastorino U, Andreola S, Tagliabue E, Pezzella F, Incarbone M, Sozzi G, Buyse M, Menard S, Pierotti M and Rilke F: Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 15: 2858-2865, 1997.
Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ and Sculier JP: Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18: 705-719, 2001.
Langendijk H, Thunnissen E, Arends JW, de long J, ten Velde G, Lamers R, Guinee D, Holden J and Wouters M: Cell proliferation and apoptosis in stage III inoperable non-small cell lung carcinoma treated by radiotherapy. Radiother Oncol 56: 197-207, 2000.
Hwang JH, Lim SC, Kim YC, Park KO, Ahn SJ and Chung WK: Apoptosis and bcl-2 expression as predictors of survival in radiation-treated non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 50: 13-18, 2001.
Graziano SL, Tatum A, Herndon JE, Box J, Memoli V, Green MR and Kern JA: Use of neuroendocrine markers, p53 and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 33: 115-123, 2001.
Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, Kris M and Dmitrovsky E: Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 55: 5038-5042, 1995.
Mascaux C, Martin B, Verdebout JM, Meert AP, Ninane V and Sculier JP: Fragile histidine triad protein expression in non-small cell lung cancer and correlation with Ki-67 and with p53. Eur Respir J 21: 753-758, 2003.
Berghmans T, Meert AP, Martin B, Ninane V and Sculier JP: Prognostic role of EGF-receptor in stage III non-small cell lung cancer. Eur Respir J 25: 329-335, 2005.
Sculier JP, Paesmans M, Lafitte JJ, Baumohl J, Thiriaux J, van Cutsem O, Recloux P, Bureau G, Berchier MC, Zacharias C, Mommen P, Bosschaerts T, Berghmans T, van Houtte P, Ninane V and Klastersky J: A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. European Lung Cancer Working Party. Ann Oncol 10: 295-303, 1999.
Sculier JP, Lafitte JJ, Berghmans T, van Houtte P, Lecomte J, Thiriaux J, Efremidis A, Koumakis G, Giner V, Richez M, Corhay JL, Wackenier P, Lothaire P, Paesmans M, Mommen P and Ninane V: A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer. Ann Oncol 15: 399-409, 2004.
Martin B, Verdebout JM, Mascaux C, Paesmans M, Rouas G, Verhest A, Ninane V and Sculier JP: Expression of p53 in preneoplastic and early neoplastic bronchial lesions. Oncol Rep 9: 223-229, 2002.
Mitsudomi T, Oyama T, Nishida K, Ogami A, Osaki T, Nakanishi R, Sugio K, Yasumoto K and Sugimachi K: p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival. Ann Oncol 6(Suppl 3): S9-13, 1995.
Meert AP, Martin B, Verdebout JM, Paesmans M, Berghmans T, Ninane V and Sculier JP: Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer. Lung Cancer 44: 295-301, 2004.
